COST

971.06

-2.65%↓

159.11

+1.2%↑

64.39

-0.05%↓

93.97

-0.18%↓

SYY

87.64

+1.35%↑

COST

971.06

-2.65%↓

159.11

+1.2%↑

64.39

-0.05%↓

93.97

-0.18%↓

SYY

87.64

+1.35%↑

COST

971.06

-2.65%↓

159.11

+1.2%↑

64.39

-0.05%↓

93.97

-0.18%↓

SYY

87.64

+1.35%↑

COST

971.06

-2.65%↓

159.11

+1.2%↑

64.39

-0.05%↓

93.97

-0.18%↓

SYY

87.64

+1.35%↑

COST

971.06

-2.65%↓

159.11

+1.2%↑

64.39

-0.05%↓

93.97

-0.18%↓

SYY

87.64

+1.35%↑

Home・Aktien・Lifecore Biomedical Inc

Lifecore Biomedical Inc

Geschlossen

BrancheKonsumgüter defensiv

7.37 -0.14

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.15

Max

7.58

Schlüsselkennzahlen
By Trading Economics
Einkommen	-7.9M -10M
Verkäufe	-5.3M 31M
Gewinnspanne	-32.116
Angestellte	406

Dividenden
By Dow Jones
Nächstes Ergebnis	13. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	31M 272M
Vorheriger Eröffnungskurs	7.51
Vorheriger Schlusskurs	7.37

Nachrichtenstimmung

By Acuity

50%

57 / 133 Ranking in Consumer defensive

Lifecore Biomedical Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Feb. 2026, 17:25 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9. Feb. 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9. Feb. 2026, 23:43 UTC

Market Talk

Gold Falls on Possible Technical Correction -- Market Talk

9. Feb. 2026, 23:14 UTC

Market Talk

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9. Feb. 2026, 22:29 UTC

Market Talk

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9. Feb. 2026, 22:19 UTC

Market Talk

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9. Feb. 2026, 22:08 UTC

Market Talk

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9. Feb. 2026, 22:01 UTC

Ergebnisse

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9. Feb. 2026, 21:59 UTC

Ergebnisse

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9. Feb. 2026, 21:59 UTC

Ergebnisse

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9. Feb. 2026, 21:58 UTC

Ergebnisse

Friedman Industries 3Q Sales $168M >FRD

9. Feb. 2026, 21:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

9. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Feb. 2026, 21:48 UTC

Ergebnisse

Friedman Industries 3Q EPS 43c >FRD

9. Feb. 2026, 21:17 UTC

Ergebnisse

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9. Feb. 2026, 21:13 UTC

Market Talk

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9. Feb. 2026, 21:04 UTC

Ergebnisse

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9. Feb. 2026, 20:30 UTC

Market Talk

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9. Feb. 2026, 20:02 UTC

Market Talk

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9. Feb. 2026, 19:42 UTC

Market Talk

Japan's Yield Curve Expected to Flatten -- Market Talk

9. Feb. 2026, 19:31 UTC

Market Talk

Nike Seen Regaining Relevance With Consumers -- Market Talk

9. Feb. 2026, 19:27 UTC

Market Talk

Gold Climbs Back Over $5,000/oz -- Market Talk

9. Feb. 2026, 19:05 UTC

Market Talk

Nike Returns to List of Hottest Brands -- Market Talk

9. Feb. 2026, 18:19 UTC

Market Talk

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9. Feb. 2026, 17:41 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9. Feb. 2026, 17:31 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9. Feb. 2026, 17:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

9. Feb. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Feb. 2026, 17:17 UTC

Market Talk

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9. Feb. 2026, 17:16 UTC

Ergebnisse

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Peer-Vergleich

Kursveränderung

Lifecore Biomedical Inc Prognose

Rating-Konsens

By TipRanks

Buy

3 ratings

Buy

Halten

Sell

Basierend auf 3 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lifecore Biomedical Inc – Dist abgegeben haben.

Stimmung

By Acuity

57 / 133 Ranking in Konsumgüter defensiv

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.